产品说明书

Pyridoxamine 2HCl

Print
Chemical Structure| 524-36-7 同义名 : Pyridoxamine (hydrochloride);Pyridoxylamine
CAS号 : 524-36-7
货号 : A141540
分子式 : C8H14Cl2N2O2
纯度 : 97%
分子量 : 241.115
MDL号 : -
存储条件：

粉末 Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 115 mg/mL(476.95 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 120 mg/mL(497.69 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Pyridoxylamine 2HCl is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions. Pyridoxylamine limits the formation of CML ((carboxymethyl)lysine) and CEL (Nε-(carboxyethyl)lysine) and cross-linking in skin collagen and, ultimately inhibits the development of nephropathy in STZ-diabetic rats. Pyridoxylamine does not appear to function as an antioxidant since it does not prevent lipid peroxidation reactions. At the same time, it does prevent protein modification by products of lipid peroxidation, including inhibiting formation of malondialdehyde and 4-hydroxynonenal adducts on protein in Zucker rats in vivo[1]. UV-Vis spectrophotometry and fluorescence were used to measure PDA (Pyridoxylamine) reactivity for 57 chemicals including anhydrides, aldehydes, and quinones where reaction rates ranged from 116 to 6.2 × 10(-6) M(-1) s(-1) for extreme to weak sensitizers, respectively. No reactivity towards PDA was observed with the thiol-selective sensitizers, non-sensitizers and prohaptens. The PDA rate constants correlated significantly with their respective murine local lymph node assay (LLNA) threshold EC3 values (R(2) = 0.76). The use of PDA serves as a simple, inexpensive amine based method that shows promise as a preliminary screening tool for electrophilic, amine-selective skin sensitizers[2].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.15mL

0.83mL

0.41mL

20.74mL

4.15mL

2.07mL

41.47mL

8.29mL

4.15mL
参考文献

[1]Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes [published correction appears in Diabetes 2003 Jan;52(1):223. Anderson Nathan L [corrected to Alderson Nathan L]]. Diabetes. 2002;51(9):2826‐2832

[2]Chipinda I, Mbiya W, Adigun RA, et al. Pyridoxylamine reactivity kinetics as an amine based nucleophile for screening electrophilic dermal sensitizers. Toxicology. 2014;315:102‐109